Illumina, Inc. vs Ryanair Holdings plc — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while Ryanair Holdings plc trades at $54.61 (market cap $27.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.6% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Ryanair Holdings plc for 72 Days on average.
| ILMN | RYAAY | |
|---|---|---|
Market Cap | $40.43B | $27.95B |
Volume | 2,948,626 | 1,519,820 |
Sector | Health | Industrials |
52-Week High | $293.69 | $73.82 |
52-Week Low | $91.00 | $51.95 |
Typical Hold Time | 83 Days | 72 Days |
Enterprise Value | $41.79B | $25.00B |
Dividend Yield | — | 1.6% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
RYAAY trades at $56.00 with a slight 0.24% daily gain, showing mixed technical signals amid bearish moving averages but neutral oscillators. Fundamentally, the airline maintains strong profitability with 12.13% net margins and attractive valuation multiples (P/E 13.95, EV/EBITDA 6.22), though recent Q3 2026 earnings are pending against high expectations. Analyst sentiment leans bullish with 65% buy ratings, but news highlights fuel cost pressures and Boeing MAX 10 certification delays as near-term concerns.
The stock presents a value opportunity given low valuations and robust cash flow, but investors face headwinds from oil price volatility and operational challenges. Upside hinges on Q3 earnings beat and cost management, while downside risks include prolonged certification delays and weaker winter traffic. Institutional ownership trends and dividend stability ($0.44 upcoming) provide support, but macro uncertainties warrant caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →